Orbimed Advisors LLC sold $83k of SION
director at Sionna Therapeutics, Inc.. 1,875 shares at an average of $44.49, traded Dec 17, 2025, filed Dec 19, 2025.
Score components
- +15RoleDirector
- +9Trade size$83k at market
- 0Share of holdings soldSold 0.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.7%, 3m -14.1%, 6m -12.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-25-001088, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -900 | $44.50 | $40k | 3,595,986 | Dec 19, 2025 |
| Dec 18, 2025 | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -100 | $44.49 | $4,449 | 3,595,886 | Dec 19, 2025 |
| Dec 19, 2025 | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -875 | $44.49 | $39k | 3,595,011 | Dec 19, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $3.9M 85,918 shares | -3% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $3.9M 85,918 shares | -3% | |
| 32Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $447k 10,250 shares | -100% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $5.3M 115,844 shares | -4% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $5.3M 115,844 shares | -4% | |
| 3Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $4,493 101 shares | -0% | |
| 3Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $4,493 101 shares | -0% | |
| 28Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $13M 292,952 shares | -10% | |
| 28Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $13M 292,952 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.